Dydroboon contains Dydrogesterone. Dydroboon uses:
Treatment of progesterone deficiencies such as:
|Therapeutic Class:||Female Sex hormones|
|Manufacturer:||MANKIND PHARMACEUTICALS LTD|
|Last Updated:||2020-11-20 18:15:00|
Dydroboon contains Dydrogesterone 10.0 Mg. Dydroboon doses
Recurrent miscarriage: 10 mg bid given cyclically until conception, then continuously until wk 20 of pregnancy, after which dose may be gradually reduced.
Infertility: 10 mg bid.
Menstrual disorders: 10 mg bid in a cyclical regimen.
Endometriosis: 10 mg bid-tid cyclically or continuously.
Threatened miscarriage: Initially, 40 mg followed by 10 mg or more every 8 hr, continued for a wk after symptoms are relieved. Reduce dose gradually after that unless symptoms return.
Endometrial protection during menopausal hormonal replacement therapy: 10 mg 1-2 times daily in a cyclical regimen or 5 mg daily.
Dizziness, nausea, headache, fatigue, emotional lability, irritability; abdominal pain and distention; muskuloskeletal pain.
Dydroboon is a progestogen structurally related to progesterone. However, unlike progesterone, it does not induce an increase in temp nor inhibit ovulation and may be preferred over other progestational agents when contraceptive effect is not required. It does not have oestrogenic or androgenic properties.
Monitor closely for loss of vision, proptosis, diplopia, migraine, signs and symptoms of embolic disorders. CVD or renal impairment, epilepsy, asthma, other conditions which may be aggravated by fluid retention. Lactation.
Carbamazepine, griseofulvin, phenobarbital, rifampicin enhances the clearance of progestogens.
From spontaneous surveillance systems to date, there is no evidence that dydrogesterone can not be used during pregnancy.
Dydroboon is excreted in the milk of nursing mothers. A risk to the suckling child cannot be excluded. Dydroboon should not be used during breast-feeding.
There is no evidence that dydrogesterone decreases fertility at therapeutic dose.
Hypersensitivity to the active substance or to any of the excipients. Known or suspected progestogen dependent neoplasms. Undiagnosed vaginal bleeding
Limited data are available with regard to overdose in humans. Dydroboon was well tolerated after oral dosing (maximum daily dose taken to date in humans 360 mg). No reports of ill-effects from overdose have been recorded. If a large overdose is discovered within two or three hours and treatment seems desirable, gastric lavage is recommended. There are no specific antidotes and treatment should be symptomatic. Aforementioned information is also applicable for overdosing in children.
Do not store above 30˚C. Keep in a dry place. Keep the blister in the outer carton, in order to protect from moisture.
Dydroboon Tablet price in India 425